Scale -


  • Revenue is 642 Rs Cr; Annual Growth is 28 %; Continuous Growth over 3 years; 5 Year CAGR is 14 %
  • Ebitda is 250 Rs Cr; Annual Growth is 26 %; Continuous Growth over 3 years; 5 Year CAGR is 36 %
  • PBT is 54.29 Rs Cr; Annual Growth is 25 %; 5 Year CAGR is 38 %
  • PAT is 174 Rs Cr; Annual Growth is 26 %; Continuous Growth over 3 years; 5 Year CAGR is 41 %

Profitability -


  • PBDIT Margin is 39 %; in Top Quartile; 5 Year CAGR is 19 %; Continuous Decline over 3 years
  • PAT Margin is 27.13 %; in Top Quartile; 5 Year CAGR is 23 %; Continuous Decline over 3 years
  • Quarterly Ebitda Margin is 35 %; in Top Quartile
  • Quarterly Profit margin is 26 %; in Top Quartile; Continuous Decline over 3 Quarters

Return -


  • ROCE is 24.22 %; in Top Quartile; Annual Decline is -30 %; Continuous Decline over 3 years
  • ROA is 14.71 %; in Top Quartile; Annual Decline is -24 %; Continuous Decline over 3 years
  • ROE is 19.57 %; in Top Quartile; Annual Decline is -31 %; Continuous Decline over 3 years
  • Asset Turnover is 68 %; Continuous Decline over 3 years

Efficiency -


  • Operating cash flow is 69.55 Rs Cr; Annual Growth is 43 %
  • Current Ratio is 3.09; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 32 %
  • Quick Ratio is 2.02; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 30 %
  • Inventory Turnover Ratio is 3.73; Continuous Decline over 3 years

Solvancy -


  • Debt/Equity is 0.17; Annual Decline is -39 %; 5 Year CAGR is -23 %
  • Contingent Liabilities is 50.76 Rs Cr; Annual Decline is -61 %; 5 Year CAGR is 96 %
  • Total Debt is 148 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 22 %

Quality -


  • Change in Inventories/Total Expenses is -10 %; in Bottom Quartile
  • Operating cashflow/ebitda is 28 %; in Bottom Quartile; 5 Year CAGR is -17 %
  • Exceptional Items/PBT is 0 %; in Top Quartile
  • Other Expenses/Total Expenses is 32 %; in Top Quartile
  • Operating cashflow/PAT is 40 %; 5 Year CAGR is -20 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Earnings call transcript: Sudeep Pharma posts record Q2 2027 revenue, EBITDA By Investing.com
Sudeep Pharma (NSE:SUDEEPPHRM) Q2 FY27 Results and Capacity Update
Sudeep Pharma Q2 FY27 slides: 32% EBITDA growth, battery push accelerates By Investing.com
Sudeep Pharma gets FDA nod for new Gujarat facility
Sudeep Pharma Q2FY27 results: EBITDA rises 32% YoY to ?73.2 crore
Sudeep Pharma (BSE:544619)
Sudeep Pharma Receives Gujarat FDA Approval for New Nandesari Manufacturing Facility
Sudeep Pharma gets FDA approval for new 51,200 MT capacity plant in Gujarat
Sudeep Pharma Ltd
Sudeep Pharma publishes notice for 37th AGM
Sudeep Pharma Receives FDA Approval For 51,200 MT Greenfield Facility In Nandesari
Sudeep Pharma Limited (SUDEEPPHRM.NS) stock major holders
Sudeep Pharma Holds Above ?1,000 as SUDEEPPHRM.NS Grinds Higher
Sudeep Pharma Shares: Rs 1,000 Target Below CMP, What to Do
Sudeep Pharma Share Price and Technical Analysis
Sudeep Pharma (SUDEEPPHRM.NS) Slips 1.28% to ?1158.4, Holding Midway Between ?1100.48 Support and ?1216.32 Resistance
Sudeep Pharma reports cessation of SMP Sendhil Pani